Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
about
Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptorStructure and function of steroid receptor AF1 transactivation domains: induction of active conformationsSingle-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathwaysCrystal structure of human sex hormone-binding globulin: steroid transport by a laminin G-like domainEstradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and betaA preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and womenIn vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosusERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminusEstrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer.Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptorsEstrogen receptor transcription and transactivation: Basic aspects of estrogen action.Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapyProblems for risk assessment of endocrine-active estrogenic compoundsInteraction of organophosphate pesticides and related compounds with the androgen receptorHormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment ConsiderationsMolecular Mechanisms of Action of BPACrystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insectsCrystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonismCrystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosteroneThe structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alphaThe three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonismInsights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligandsThe 2.0 Å crystal structure of the ERα ligand-binding domain complexed with lasofoxifeneMolecular basis for dimer formation of TRβ variant D355RThe “Phantom Effect” of the Rexinoid LG100754: Structural and Functional InsightsDevelopment of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core LigandsX-ray Structures of Progesterone Receptor Ligand Binding Domain in Its Agonist State Reveal Differing Mechanisms for Mixed Profiles of 11 -Substituted SteroidsThe orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPKSoy and Health Update: Evaluation of the Clinical and Epidemiologic LiteratureAntiestrogens: structure-activity relationships and use in breast cancer treatmentImportance of Estrogenic Signaling and Its Mediated Receptors in Prostate CancerSKF-82958 is a subtype-selective estrogen receptor-alpha (ERalpha ) agonist that induces functional interactions between ERalpha and AP-1Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedingsFunctional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and bindingEstrogenicity and androgenicity screening of PCB sulfate monoesters in human breast cancer MCF-7 cellsDietary boron and hormone replacement therapy as risk factors for lung cancer in womenMenopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers StudyExogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptorsThe phytoestrogen genistein affects zebrafish development through two different pathways
P2860
Q24313503-FB6587E9-89E2-4878-8205-865CECDC109AQ24537137-83B516C0-42CD-40E0-834E-2F25F85E1D4CQ24562820-FD27AF18-DEC9-478D-82E7-E10934068EEBQ24601344-33B8493C-E5E1-463F-9243-32CB837C6252Q24632806-9EFDD41D-AD60-430B-8CA3-798D209FE4B8Q24657278-595E6BF4-1061-42CF-8FE8-01FBF92359ACQ24674880-B4872A95-416B-457D-8064-DB759165A625Q24793018-C5E8B293-1721-433D-89C9-4228BFD176F0Q24800731-4C92F7BA-F919-4507-B18D-8020E8DD7EEAQ24800777-8F72FB6F-0AE1-48D3-8CB0-F1A0378EB591Q24800814-FE4424BD-A510-4A13-8A86-261EEE44B3EDQ24803990-E1D2961E-2771-43DF-9E2B-6092D1C04472Q24812789-773705B3-79A3-439B-A406-B9A2686ABF45Q24814312-BC9CE4F6-2100-42E5-A15C-7DFAB309EAEDQ26751021-348B52D2-5710-48D8-9663-93B70A472006Q26770365-491BD086-1A56-43C6-B751-077041D90307Q27627719-0A677767-F4EF-477C-860A-68B4A672A837Q27630889-D8CD52CA-0A55-43DF-93E5-861372F7EA6BQ27631345-AEDF1825-3F1C-4FB4-A2D7-71F8A0109AC0Q27637227-C2954E92-1021-4E7B-8A4E-CDA5CB2314BAQ27638786-897B35D9-F96F-4FC6-8915-FBCDC9F7176DQ27640953-AD6071A3-AFA2-460B-881A-4D14770B87D4Q27644330-8C0CD91F-90F5-4AED-AB08-11441630D52EQ27644597-4097F22F-2694-4CF6-8028-0236C0117F94Q27652190-529A8514-92F8-4CC4-8330-25E88A1A0F38Q27666286-ABBF3058-7469-489D-BEFB-B83637349AF0Q27678627-DCA297FF-DBC8-43B5-A27A-52B6F0536C8DQ27678748-67E13BD1-9920-4CFA-9F7A-335585491B7DQ27682265-4A446041-D913-4B19-B0D0-65205F0E9394Q28071946-E7C7B12B-EA45-42D8-B0B7-62B11B3A2B0EQ28077245-ABDCD12D-C4E7-43E6-B5D0-82BD024740D4Q28077543-B640D0C5-D23F-471B-8CDC-12BD594C3F01Q28204373-AFBAEB62-F40D-49CB-8480-06638FD4A422Q28264426-D7A4CBBA-AF8B-4835-B589-ABF8EC71DCA5Q28375155-1EA34F24-7D2A-40C0-8064-BFD6C389CDA8Q28384524-C956626E-9D4F-41C7-8DC5-5186C8BAD12EQ28386136-3EF7AC73-43FD-470A-88FB-E5C1DD20ACDCQ28391500-01E31336-B3B2-498A-A7BF-AB0FA38A0AA4Q28393495-5DC20A79-A304-44DB-B7D0-442D814C7AB6Q28475074-F2135B42-54BF-4BA8-A2FD-EF174AF533AE
P2860
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Structure of the ligand-bindin ...... agonist and a full antagonist
@ast
Structure of the ligand-bindin ...... agonist and a full antagonist
@en
Structure of the ligand-bindin ...... agonist and a full antagonist
@nl
type
label
Structure of the ligand-bindin ...... agonist and a full antagonist
@ast
Structure of the ligand-bindin ...... agonist and a full antagonist
@en
Structure of the ligand-bindin ...... agonist and a full antagonist
@nl
prefLabel
Structure of the ligand-bindin ...... agonist and a full antagonist
@ast
Structure of the ligand-bindin ...... agonist and a full antagonist
@en
Structure of the ligand-bindin ...... agonist and a full antagonist
@nl
P2093
P3181
P356
P1433
P1476
Structure of the ligand-bindin ...... agonist and a full antagonist
@en
P2093
A G Thorsell
A M Brzozowski
J A Gustafsson
J Ljunggren
M Carlquist
O Engström
R E Hubbard
P304
P3181
P356
10.1093/EMBOJ/18.17.4608
P407
P577
1999-09-01T00:00:00Z